Exclusive-Novartis in the lead to acquire cancer drug developer MorphoSys-sources
Go back to Exclusive-Novartis in the lead to acquire cancer drug developer MorphoSys-sources| Morgan Stanley Capital Protected Notes for S&P 500 Index (NASDAQ: MOR) | Delayed: 18.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.96 | 52 Week High | $13.71 | |||
| Open | $18.96 | 52 Week Low | $9.64 | |||
| Day High | $18.96 | P/E | N/A | |||
| Day Low | $18.96 | EPS | $0.00 | |||
| Volume | 9,959,181 | |||||
| NOVARTIS AG (NYSE: NVS) | Delayed: 161.25 +9.19 (6.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $152.06 | 52 Week High | $89.15 | |||
| Open | $162.15 | 52 Week Low | $69.84 | |||
| Day High | $163.57 | P/E | N/A | |||
| Day Low | $160.21 | EPS | $0.00 | |||
| Volume | 4,334,115 | |||||
